“Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland” (2019) Swiss Medical Weekly, 149(5152), p. w20170. doi:10.4414/smw.2019.20170.